Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 9/20 | 0.50 |
| ▸ | MGAM | O43451 | 8/20 | 0.50 |
| ▸ | SI | P14410 | 3/20 | 0.46 |
| ▸ | GBA1 | P04062 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LCT | P09848 | 1/20 | 0.46 |
| ▸ | GBA2 | Q9HCG7 | 7/20 | 0.46 |
| ▸ | UGCG | Q16739 | 3/20 | 0.46 |
| ▸ | AGL | P35573 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camiglibose SCHEMBL19510347 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL1201508 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL3952283 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL2052995 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL5186895 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL4604473 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL758524 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL5238483 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL614436 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL37446 | 0.99 | GAA (0.49) | GAAMGAMSIGBA1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723744-B2 | FOR THERAPY OF OBESITY, OVERWEIGHT CONDITION, HYPERLIPIDEMIA, GLAUCOMA, CARDIAC ARRHYTHMIAS, SKIN DISORDER, THYROID DISEASE, HYPOTHYROIDISM, THYROID CANCER, DIABETES, ATHEROSCLEROSIS, HYPERTENSION, CORONARY HEART DISEASE, HYPERCHOLESTEREMIA | PFIZER, INC. | 2004-04-20 | — | — | US | disclosed |
| US-20030078289-A1 | Indole carboxylic acids as thyroid receptor ligands | ASPNES GARY E (US) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078289-A1 | Indole carboxylic acids as thyroid receptor ligands | THRA, MC1R, THRB | GAA 4040/4885MGAM 3912/4885SI 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.